ERBB2 and cancer: Human epidermal growth factor receptor 2 (HER2) as a biomarker was proposed to be a treatment target because of its abnormal expression in OS cancer cells and association with lung metastasis, but the drug targeted to HER2 didn’t improve the survival rate of OS patients significantly33,34.